^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Urothelial Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with...Locally advanced or metastatic urothelial carcinoma...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...the NCCN panel recommends pembrolizumab, atezolizumab, nivolumab, durvalumab, avelumab, or erdafitinib as preffered second-line systemic therapy options after platinum-based therapy.